As Neola Medical reports its second quarter of 2023, much of the focus is on market preparations. Intensive work is underway with technical verification studies while the company is also preparing for both a preclinical and a clinical study. BioStock contacted CEO Hanna Sjöström to find out more about how she views the development during the quarter.

Read the article here: BioStock – Neola CEO sees exciting autumn ahead

Read the report and the press release here: Press release